Literature DB >> 10962150

iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis.

S Sasaki1, N Shibata, T Komori, M Iwata.   

Abstract

We carried out an immunohistochemical investigation of the spinal cords of 15 patients with sporadic amyotrophic lateral sclerosis (ALS), using antibodies to inducible nitric oxide synthase (iNOS) and nitrotyrosine; our purpose was to search for a possible role of increased oxidative damage in the motor system that may contribute to the neurodegenerative process in this disease. Specimens from 16 patients without any neurological disease served as controls. In the controls, normal-appearing neurons and their dendrites were negatively immunostained for iNOS. In the ALS patients, most of normal-appearing anterior horn neurons did not show iNOS immunoreactivity either in the perikarya or in their dendrites. However, many of the degenerated neurons showing central chromatolysis or simple atrophy demonstrated focally or diffusely positive iNOS immunoreactivity within the perikarya and their neuronal processes. In the neuropil of the anterior horns, the reactive astrocytes were more intensely immunostained for iNOS as compared with the controls. Some of the swollen proximal axons (spheroids) were focally or diffusely immunostained by the antibody. The corticospinal tracts demonstrated positive iNOS immunoreactivity of proliferated reactive astrocytes. The immunostaining pattern of nitrotyrosine in the anterior horn neurons of the spinal cord was similar to that of iNOS. These findings suggest that selective nitric oxide-mediated oxidative damage in the motor system plays a part in the pathomechanism of the neuronal degeneration in the spinal cord of sporadic ALS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962150     DOI: 10.1016/s0304-3940(00)01370-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  26 in total

Review 1.  Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.

Authors:  Lee J Martin
Journal:  IDrugs       Date:  2010-08

Review 2.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

Review 3.  T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?

Authors:  Stanley H Appel; David R Beers; Jenny S Henkel
Journal:  Trends Immunol       Date:  2009-10-31       Impact factor: 16.687

Review 4.  Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis.

Authors:  Wenzhi Tan; Piera Pasinelli; Davide Trotti
Journal:  Biochim Biophys Acta       Date:  2014-02-22

5.  Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation.

Authors:  Lee J Martin; Kevin Chen; Zhiping Liu
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

Review 6.  Mechanisms of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  S Cluskey; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

Review 7.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria.

Authors:  Guy C Brown; Anna Bal-Price
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

9.  Inducible nitric oxide synthase is present in motor neuron mitochondria and Schwann cells and contributes to disease mechanisms in ALS mice.

Authors:  Kevin Chen; Frances J Northington; Lee J Martin
Journal:  Brain Struct Funct       Date:  2009-11-04       Impact factor: 3.270

10.  Transcriptional profile of primary astrocytes expressing ALS-linked mutant SOD1.

Authors:  Marcelo R Vargas; Mariana Pehar; Pablo J Díaz-Amarilla; Joseph S Beckman; Luis Barbeito
Journal:  J Neurosci Res       Date:  2008-12       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.